Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-12-08 pm EST
51.78 USD   +3.07%
04:59pS&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
04:03pS&P 500 snaps losing streak on jobless claims rise
RE
03:58pFDA Authorizes Pfizer-BioNTech, Moderna COVID-19 Shots for Children as Young as Six Months
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PFIZER INC : Berenberg sticks Neutral

09/14/2022 | 04:12am EST

In a research note, Berenberg analyst Luisa Hector has maintained his recommendation on the stock with a Neutral rating. The target price is reduced from USD 50 to USD 44.


ę MarketScreener with dpa-AFX Analyser 2022
All news about PFIZER, INC.
04:59pS&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
04:03pS&P 500 snaps losing streak on jobless claims rise
RE
03:58pFDA Authorizes Pfizer-BioNTech, Moderna COVID-19 Shots for Children as Young as Six Mon..
MT
02:16pS&P 500 rebounds as investors take rate hike cues from jobless claims rise
RE
01:00pIN BRIEF: Pfizer gets US emergency approval for Omicron vaccine
AN
12:26pFDA approves Moderna, Pfizer bivalent COVID-19 vaccines for youngest kids
AQ
11:45aPfizer/BioNTech's Bivalent COVID-19 Shot Gets US Approval for Children Ages Six Months ..
MT
11:38aPfizer, BioNTech Secure FDA Authorization for Updated COVID-19 Vaccine for Young Childr..
MT
10:51aFDA clears updated COVID-19 vaccines for kids under age 5
AQ
10:44aPfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-..
BU
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 100 B - -
Net income 2022 33 343 M - -
Net cash 2022 4 548 M - -
P/E ratio 2022 9,12x
Yield 2022 3,12%
Capitalization 291 B 291 B -
EV / Sales 2022 2,85x
EV / Sales 2023 3,56x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 51,78 $
Average target price 53,78 $
Spread / Average Target 3,86%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-15.82%282 013
JOHNSON & JOHNSON2.94%463 208
ELI LILLY AND COMPANY33.42%353 438
ABBVIE INC.22.16%292 407
NOVO NORDISK A/S20.94%283 266
MERCK & CO., INC.43.65%279 122